---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-005648"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T13:43:00.458711+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SELLAS announces positive interim analysis for Phase 3 REGAL trial of GPS in AML; IDMC recommends continuation

## Summary
- IDMC recommended continuation of Phase 3 REGAL trial after interim analysis triggered by 60 deaths; no safety concerns.
- Blinded data: fewer than 50% of patients deceased after median follow-up of 13.5 months; pooled median survival >13.5 months vs ~6 months historical.
- Blinded immune response: 80% of GPS patients showed GPS-specific T-cell response, exceeding prior Phase 2 result of 64%.
- Next final analysis planned at 80 events, expected in 2025; company preparing BLA submission.

## SEC filing metadata
- accession: 0001104659-25-005648
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/0001104659-25-005648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/tm254291d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-005648
- JSON: https://secwatch.observer/filing/0001104659-25-005648.json
- Plain text: https://secwatch.observer/filing/0001104659-25-005648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.